HomeAI · summaries
Storia in 3 fonti
Parabilis' $670M IPO sets new biotech record, will fund cancer drug
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss; Parabilis boosts IPO target to $553M net proceeds.
- ·
biopharmadive.com
Parabilis sets a record with a $670M biotech IPO
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion…
- ·
Parabilis' $670M IPO sets new biotech record, will fund cancer drug
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.
- ·
cryptobriefing.com
Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range
Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 million Regeneron private placement.
- ·
'Going for our own moonshot': Parabilis CEO on biotech's record IPO
Parabilis Medicines CEO Mathai Mammen speaks about the biotech's record $670M IPO, its desmoid tumor pipeline and plans beyond oncology.